SEC Form 4 · accession 0001869194-26-000008
ARDELYX, INC. · ARDX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Laura A Williams
Officer — Chief Patient Officer
Period of report
Jun 18, 2026
Accepted (ET)
Jun 22, 2026 · 4:01 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001437402
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jun 18, 2026 | M | 31,000 | $0.99 | A | 460,093 | D | |
| Common StockF2 | Jun 18, 2026 | S | 81,898 | $5.989 | D | 378,195 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F3 | $0.99 | Jun 18, 2026 | M | 31,000 | D | — | Jan 6, 2032 | Common Stock | 31,000 | 31,000 | D |
Explanation of responses
- F1Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 19, 2026.
- F2Transaction was executed in multiple trades in prices ranging from $5.97 to $6.0086, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- F3The option becomes exercisable as it vests and the shares subject to the option vest in 48 successive, equal monthly installments on each monthly anniversary of January 6, 2022, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date.
Remarks
Exhibit 24.1 - Power of Attorney